Evidence map›Paper›PMID 40549304›Full record

ReviewMolecular and cellular biochemistry2025

The challenges and progress of CAR-T cell therapy in the treatment of solid tumors.

Kai Cui, Wanjun He, Na Huang, Songshan Zhu, Dan Jiang, Weiqiang Yang, Yiwei Zeng, Muhammad Asad Farooq, Guangxian Xu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kai Cui *Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
Wanjun He *Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
Na HuangGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
Songshan ZhuGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
Dan JiangGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
Weiqiang YangGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
Yiwei ZengGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
Muhammad Asad FarooqGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523808, Guangdong, China.ORCID http://orcid.org/0000-0002-8792-4171
Guangxian XuGuangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523808, Guangdong, China. xuguangxian@gdmu.edu.cn.ORCID http://orcid.org/0000-0002-0481-9625

Funding

Guangdong Basic and Applied Basic Research Foundation 2023A1515140148Ningxia Key R&D Program 2022CMG02041the High-level Talent Research Funding Program of the First Dongguan Affiliated Hospital of Guangdong Medical University GCC2023004
6 · The paper itself

Abstract

Current traditional cancer treatment methods include surgery, chemotherapy, radiotherapy, etc., which lack targeted killing functions and may damage normal tissues. Immunotherapy, targeted therapy, and personalized medicine have become promising methods for cancer treatment, providing more precise and effective treatment for patients. Among them, chimeric antigen receptor (CAR)-T cell therapy utilizes the immune system's T cells to recognize and attack tumor cells, showing promising therapeutic prospects. The FDA has approved CAR-T therapy for treating B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma, targeting CD-19 and B-cell maturation antigens. Despite success in hematologic cancers, CAR-T technology faces challenges in solid tumors, including a lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T cell infiltration. This review covers the advantages and disadvantages of various immunotherapy methods, highlights CAR-T therapy's evolution, summarizes CAR-T therapy's current status, lists promising therapeutic targets, and emphasizes the challenges CAR-T cell therapy faces.

Indexed as

Immunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenAnimalsAntigens, NeoplasmHumansT-LymphocytesAntigens, NeoplasmReceptors, Chimeric AntigenCAR-T cell therapyImmunotherapyLimitationSolid tumorTumor-associated antigens

Identifiers

PMID40549304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.